Focus on Diabetes Care

Back to articles

Another favorable CV study for an antidiabetic agent


Addition of liraglutide (Victoza—Novo Nordisk) to standard of care therapy in patients with type 2 diabetes at high risk for cardiovascular (CV) events resulted in a reduced risk of adverse CV outcomes.


Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.

Ingelfinger JR, et al. Cardiac and renovascular complications in type 2 diabetes—is there hope? N Engl J Med. 2016;375:380–2.